Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Clinical Management of ROS1+ Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

ROS1 Alterations in Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

October 23rd 2021

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.

Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC

October 22nd 2021

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC

October 22nd 2021

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

Second-Line Metastatic NSCLC: Treatment Landscape and Challenges

October 22nd 2021

Rebecca Suk Heist, MD, MPH, discusses the treatment landscape and challenges when treating patients with second-line metastatic non-small cell lung cancer.

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLC

October 20th 2021

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

Dr. Patel on the Utility of Consolidative Durvalumab in Stage III NSCLC

October 20th 2021

Sandip P. Patel, MD, discusses the utility of consolidative durvalumab in stage III non–small cell lung cancer.

Chemoimmunotherapy Combos, Adjuvant Approaches and Bispecifics Are Among Exciting Advances in Lung Cancer

October 19th 2021

The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.

Novel Sintilimab Combo Significantly Improves PFS in EGFR-Mutated Nonsquamous NSCLC

October 18th 2021

The combination of sintilimab, a bevacizumab biosimilar injection, and chemotherapy resulted in a significant improvement in progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer that as progressed following treatment with an EGFR TKI, meeting the primary end point of the phase 3 ORIENT-31 trial.

Cemiplimab Earns High Marks in First-Line Treatment of Advanced NSCLC

October 18th 2021

Ahmet Sezer, MD, discusses how the approval of cemiplimab could potentially make a huge impact for patients with advanced non–small cell lung cancer.

Clinical Management of ALK+ Advanced NSCLC

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.

ALK Alterations in Advanced NSCLC

October 18th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.

Dr. Johnson on Datopotamab Deruxtecan in NSCLC With Actionable Genomic Alterations

October 15th 2021

Melissa L. Johnson, MD, discusses the emergence of datopotamab deruxtecan in non–small cell lung cancer with actionable genomic alterations.

FDA Approves Adjuvant Atezolizumab for Select Stage II to IIIA NSCLC

October 15th 2021

The FDA has approved atezolizumab for use as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

Future Strategies With Lung Cancer Screening

October 14th 2021

M. Patricia Rivera, MD, a professor of medicine at The University of North Carolina at Chapel Hill, reviews the United States Preventive Services Task Force's lung cancer screening recommendations as of 2021, including the impacted patient populations and effect the recommendations have on direct physician care.

Utilizing Patient-Friendly Pathways in Lung Cancer Diagnostics and Treatment

October 13th 2021

Andrea Borondy Kitts, a lung cancer and patient advocate at Rescue Lung Society, educates physicians on adequate physician-to-patient education and resources that improve their opportunity for success in lung cancer care.

Dr. Li on the Limitations of the IMpower010 Trial in Resected Stage IB-IIIA NSCLC

October 13th 2021

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

Novel Agents Emerging in the Lung Cancer Pipeline

October 13th 2021

Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, describes the last decade in lung cancer diagnostics and significant therapeutic advances. He also navigates the emerging classes of drugs that are beginning to make headway in the lung cancer pipeline.